Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Trial Parameters
Brief Summary
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
Eligibility Criteria
Inclusion Criteria: 1. Age ≥14 years, gender not specified; 2. Diagnosed with B-ALL according to the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue tumors (2022 version); 3. Meet the diagnosis of relapsed/refractory leukemia, excluding isolated extramedullary relapse; For relapsed or refractory B-ALL, including any of the following situations: a) Relapse: Peripheral blood or bone marrow recurrence of primitive cells \>5% or extramedullary lesions appear again after complete remission; b) Refractory: Primary refractory patients who fail to achieve complete remission after standard induction chemotherapy；those with positive measurable residual disease can also be included； 4. Flow cytometry confirms positive CD19 expression in leukemia cells； 5. Estimated survival \>3 months; 6. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2; 7. The vital organs function in accordance with the following requirements: 7.1Left ventricular ejection